Thermo Fisher Live Event Shorts

  1. Overcoming Capacity Constraints 11/13/2023

    How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.

  2. Market Demand For AAV Vectors 11/13/2023

    Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.

  3. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

  4. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  5. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  6. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

  7. Safety And Efficiency Of Source Material Collection 8/18/2023

    Expert CTO's detail how automation improves safety and efficiency when collecting source material.

  8. Auto, Allo, And AI 8/18/2023

    CTO experts debate autologous and allogeneic, and how automation improves the CAR-T cell process every step from collection to infusion. They also discuss the major ways AI optimizes automation.

  9. Pipeline Progress 8/18/2023

    Experts working on robust pipelines that focus on various therapeutic areas explain how process automation looks different per therapeutic focus area.

  10. Mitigating Risk In Process Automation 8/18/2023

    Two Chief Technical Officer's for therapeutic organizations cover the various ways in which automation helps to reduce risk and why closing systems and reducing the number of manual manipulations is so critical.